In the first funding period (2018 – 2022), the foundations have already been laid and data from hospital care has been made available for research. This has been implemented within the MIRACUM consortium, one of the consortia represented in MII, which brings together 10 university hospitals. Data protection should be particularly emphasized here: the patient data remains in the respective institution and is evaluated locally. To ensure anonymity, only aggregated values are passed on, for example the average value for a particular parameter. Only if patients have given their consent can their data be further processed in a so-called “pseudonymized form”. Pseudonymized means that information that could identify the patient has been removed (e.g. name, address), but that, for example, a key is stored with which authorized persons can assign the data to a patient.
We have determined the state of the art in science and technology in the areas affected by this project through current information research. To the best of our knowledge, the project is not already the subject of other research, developments, investigations or patents and there are no industrial property rights or applications for industrial property rights to prevent the project from being carried out and the results from being used at a later date.
COPD and asthma: longitudinal and cross-sectoral real-world data for machine learning application for quality improvement and knowledge acquisition – CALM-QE (EAACI Congress 31.05.2024) Gallery
